- Home
- ESLA vs NOTV Comparison
ESLA vs NOTV Comparison
Compare ESLA & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESLA
- NOTV
- Stock Information
- Founded
- ESLA 2021
- NOTV 1974
- Country
- ESLA United States
- NOTV United States
- Employees
- ESLA N/A
- NOTV N/A
- Industry
- ESLA Biotechnology: Biological Products (No Diagnostic Substances)
- NOTV Biotechnology: Pharmaceutical Preparations
- Sector
- ESLA Health Care
- NOTV Health Care
- Exchange
- ESLA Nasdaq
- NOTV Nasdaq
- Market Cap
- ESLA 41.6M
- NOTV 40.4M
- IPO Year
- ESLA N/A
- NOTV 1997
- Fundamental
- Price
- ESLA $0.91
- NOTV $3.59
- Analyst Decision
- ESLA
- NOTV Strong Buy
- Analyst Count
- ESLA 0
- NOTV 3
- Target Price
- ESLA N/A
- NOTV $5.92
- AVG Volume (30 Days)
- ESLA 16.9K
- NOTV 509.8K
- Earning Date
- ESLA 11-14-2024
- NOTV 12-03-2024
- Dividend Yield
- ESLA N/A
- NOTV N/A
- EPS Growth
- ESLA N/A
- NOTV N/A
- EPS
- ESLA N/A
- NOTV N/A
- Revenue
- ESLA N/A
- NOTV $501,062,000.00
- Revenue This Year
- ESLA N/A
- NOTV N/A
- Revenue Next Year
- ESLA N/A
- NOTV $8.69
- P/E Ratio
- ESLA N/A
- NOTV N/A
- Revenue Growth
- ESLA N/A
- NOTV N/A
- 52 Week Low
- ESLA $0.63
- NOTV $1.23
- 52 Week High
- ESLA $3.23
- NOTV $11.42
- Technical
- Relative Strength Index (RSI)
- ESLA 53.92
- NOTV 76.70
- Support Level
- ESLA $0.74
- NOTV $2.56
- Resistance Level
- ESLA $0.99
- NOTV $3.78
- Average True Range (ATR)
- ESLA 0.09
- NOTV 0.45
- MACD
- ESLA 0.02
- NOTV 0.08
- Stochastic Oscillator
- ESLA 72.88
- NOTV 88.73
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.
About NOTV Inotiv Inc.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery and development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, it supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through the RMS segment, it offers access to a wide range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas. It earns maximum revenue from RMS Segment.